Read the latest news and explore the latest media coverage about Jeeva
Clinical Trials Need More Diversity—This Tech Company is Trying to Change That
Studies have found that when people with diverse backgrounds are not adequately represented, treatments shown to be effective in trials may not be effective for all populations. This is why focusing on diversity in clinical trials is critical from this point forward.
Distrust, Fear Hamper COVID Vaccinations, Clinical Trial Diversity
The medical research community needs to plan and work toward earning the trust of diverse patients in both in-person and online settings. It cannot be assumed or taken for granted. To help overcome the lingering effects of these long-ago but well-remembered occurrences, says Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics Solutions Inc., it is necessary to address patients’ fears with real facts and real data. Prospective clinical trial participants need to understand as clearly as possible what they are consenting to, what the risks might be, and how the potential results will benefit mankind.
Healthcare Innovators to Change How Industry Communicates Telehealth
Companies that organize and conduct clinical drug trials are challenged to find and retain participants. Current statistics show that 85% of all clinical trials are delayed during patient recruitment, and 30% are terminated early due to failure to enlist enough patients. Even the small proportion of trials that manage enroll the required number experience an average 30% dropout rate. However, there are companies bringing fully scalable modular software-as-a-service platform to facilitate patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device, effectively bringing much of the trial processes to the participant.
Patient-Centric Approach to Clinical Trials Improves Outcomes for All Stakeholders
According to researchers at the MIT Sloan School of Management, the probability of FDA approval of an industry-sponsored drug entering Phase One of the clinical trial process is 13.8%. A major factor in a trial’s success or failure, notes Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics Solutions Inc., is the trial sponsor’s ability to recruit and retain patients.
Decentralized Clinical Trials Boost Enrollment, Increase Patient Diversity
As medical centers were forced to focus on COVID-related care, and optional travel was curtailed by the need for physical distancing, patients’ access to clinical trial sites was reduced by some 80%. In response, notes Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics, sponsors have moved rapidly to shift as much clinical trial activity as possible from centralized locations to the patients’ homes or nearby facilities such as pharmacies—with positive results. “Decentralization,” says Dr. Rajasimha, “has proven to be highly beneficial to sponsors and patients alike, and to significantly improve patient diversity, recruitment, and retention.”
August 25, 2021
Jeeva Joins the Amazon Web Services Partner Network (APN)
Jeeva was named a digital innovation finalist for advancing pediatric rare disease research in the Bear Pack contest
August 15, 2021
Customer Case Study Announcement
A large US research University has signed up with Jeeva to run a 5-year longitudinal cohort study with 2500 participants on the Jeeva software. The academic research team will be transitioning over to Jeeva eClinical cloud a as single integrated platform and will retire the 3 different tools they were previously using. Their evaluation and pilot ran for the last several months.
August 01, 2021
Jeeva Wins the IGNITE Grant by Prince William County in Virginia
Jeeva is pleased to announce its selection as a winner of the competitive Prince William County IGNITE grant in Virginia. Prince William County’s IGNITE grant offers cash to selected high-growth companies and tech catalyst organizations. The $50,000 non-dilutive grant help Jeeva further commercialize the Jeeva eClinical Cloud in the thriving Bioscience park in PWC, commonwealth of Virginia, and beyond.
August 17, 2021
Removing Logistical Burdens, Maximizing Technological Solutions Could Improve Diversity in Clinical Trials
How Jeeva’s Technology Can Make An Important Impact In Our Overall Wellness
Our founder and CEO Harsha K. Rajasimha sat down with Authority Magazine's Dave Philistin for an in-depth interview about his entrepreneurial journey and mission to improve health outcomes through eClinical technology.
New Technology to Help Increase Patient Diversity in Clinical Trials
Patient test groups for new drugs and treatments, notes Dr. Harsha Rajasimha of Jeeva Informatics, tend to be non-diverse. However, recently developed digital health technologies can help broaden participation while reducing the logistical burden on both patients and study teams.
Cancer Genetics is a global company whose state-of-the-art diagnostic technologies help determine what will work best for each individual cancer patient and light a path for biophamaceurtical companies working with immunotherapies.
Jeeva was positioned in the Everest Group's inaugural #PEAKmatrix on Decentralized Clinical Trial Products for 2021
Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices carried by a patient without the need to visit a site, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, and improved data quality.
Virginia awards grants to Tysons tech businesses for commercial research projects
Tysons Corner, VA: Two technology companies in Tysons have each received $100,000 grants as part of a new state initiative intended to support projects that turn research into commercial products or services. Gov. Ralph Northam announced yesterday (Monday) that Virginia will award $3.4 million in grants to 34 small, technology-focused businesses for the inaugural round of the Commonwealth Commercialization Fund (CCF), which launched in 2020 to help advance promising technology through the development process.
Governor Northam Announces $3.4 Million to Advance Research Commercialization in Key Technology Sectors
RICHMOND—Governor Ralph Northam today announced that 34 small technology-focused businesses in Virginia will receive a total of $3.4 million in Commonwealth Commercialization Fund (CCF) grants to commercialize research in an array of sectors, including agricultural and environmental technologies, autonomous systems, clean energy, cybersecurity, data analytics, life sciences, and space and satellites. These awards mark the inaugural funding round for CCF, which was developed through the Virginia Innovation Partnership Authority (VIPA).
Kennesaw State University completes a pilot study on the Jeeva eClinical Cloud Platform
Jeeva announced the completion of a collaborative project with Kennesaw State University comparing the usability of Jeeva eClinical cloud with the REDCap software that has been in use for 5000 academic institutions worldwide. The results are pending peer-review for a journal publication anticipated in Fall 2021.
Patient Recruitment is the Elephant Slowing the Speed of Clinical Trials
Clinical trials are the regulatory mechanisms agencies like the Food and Drug Administration (FDA) use to evaluate and review evidence of safety and efficacy of investigational medicines in humans.
With the cost of discovery and development of one novel therapy exceeding $2.5 billion over a duration of 10-15 years, according to a 2018 PhRMA report, initiating, conducting, and successfully completing a clinical trial of any kind is one of the most complex endeavors.
World Virtual Clinical Trial Service Providers Market 2020-2025, by Type of Therapeutic Area, End-Users, Phase of Development and Key Geographies
Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trial Service Providers Market by Type of Therapeutic Area, End-Users, Phase of Development (Phase I, Phase II, Phase III and Phase IV), and Key Geographies: Industry Trends and Global Forecasts, 2020-2050" report has been added to ResearchAndMarkets.com's offering.
Source: Research and MarketsRead full story
January 28, 2021
Jeeva Informatics Hosts Rare Disease Panel on Decentralized, Patient-Focused Clinical Trials
In recognition of Rare Disease Day 2021, Jeeva Informatics (Jeeva) brought together a panel of experts to discuss the importance of transforming the clinical trial process for rare diseases. The panel included Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases; Thomas Lester, Former Executive Director, Audentes Therapeutics; Scott Schliebner, Senior Vice President, Scientific Affairs & Therapeutic Expertise, PRA Health Sciences; and Dr. Eric Sid, Program Director, National Center for Advancing Translational Science, Office of Rare Disease Research, (NCATS)/NIH.
January 08, 2021
Jeeva Founder and CEO to Present to Investors at the 39th Annual JP Morgan Healthcare Conference January 11-14, 2021
Jeeva AI-driven eClinical cloud accelerates #clinicalresearch at scale with remote touchless patient recruitment and patient retention.
Schedule an appointment with on the BIO one on one partnering portal or here: https://lnkd.in/gyQHab9.
We look forward to kicking off the year with #JPM2021.
December 16, 2020
Jeeva's perspective article published on the Patient Worthy portal
Avoid These 5 Real-World Data Pitfalls When Planning your Patient Registry, Natural History, or Other Clinical Study for a Rare Disease
1. Don’t toggle between multiple software to manage the study.
2. Don’t expect your clinical team to manually configure & execute the study.
3. Don’t confuse informed consent with collecting signatures (electronic or otherwise).
4. Don’t skip planning for travel restrictions that could halt in-person office visits.
5. Don’t limit your study participants to a specific mobile device manufacturer.
May 13, 2020
Jeeva to present at the KiwiTech's First Online Version of its Minority Founders Demo Day
KiwiTech, a tech startup accelerator that helps early to growth-stage startups in their product development drive traction and access capital, announced that it will host the 4th edition of its Minority Founders Demo Day on May 14, 2020, virtually for the first time.
April 08, 2020
KiwiTech and Jeeva Informatics Solutions Announce Strategic Partnership
Washington, DC: KiwiTech, LLC, an innovation platform that helps startups build viable products, drive traction, and raise capital, today announced a strategic partnership with Jeeva Informatics Solutions Inc, an AI-driven startup that builds patient-focused big data and digital health solutions for accelerating clinical research.
March 12, 2020
Speeding Up the Search for Cures – Jeeva Informatics Solutions
By any measure, Harsha Rajasimha, PhD, was a successful man. He had published journal articles and chapters in professional textbooks; he had received patents, honors, and awards for his work. But none of these accomplishments equipped him to help his baby, who died from Edwards Syndrome, a rare congenital disease.
Source: America's SBDC
This Startup is on a Mission to Decentralize Cell and Gene Therapy Clinical Trials
For the cell and gene therapy revolution to be fully realized, physicians, research scientists, biomanufacturing experts, advocacy groups, regulatory bodies like the Food & Drug Administration (FDA) and other key stakeholders have to “Think Different”, as Apple famously encouraged.
Jan. 29, 2020
Five Biotechs Poised to Advance Their Rare Disease Programs in 2020
The Biohealth Capital Region (BHCR) is at the leading edge of the rare disease market with companies like American Gene Technologies, REGENXBIO, Cerecor, Asklepion Pharmaceuticals, Lediant, and others advancing their pipelines towards rare disease treatments and cures. The region’s robust rare disease sector also includes a host of companies that support rare disease research and development like Jeeva Informatics, GeneDx, Aperiomics and HemoShear among others. In short, the portfolio of rare disease companies and growing support ecosystems make the BHCR a global hub for rare disease R&D.
Source: Steve Surdez, StoryCore contribution to BioBuzz.io
Jan. 08, 2020
CIT GAP Funds Invests in Jeeva to Decentralize and Improve Clinical Trial Operations
The Center for Innovative Technology (CIT) today announced that CIT GAP Funds has invested in Herndon, Va.-based Jeeva Informatics Solutions Inc. (Jeeva), a precision medicine data science company focused on significantly accelerating clinical trial operations by taking trials to patients’ homes. Using AI and digital health technologies, Jeeva fast tracks patient recruitment, improves adherence to trial protocols, and reduces patient burden and dropout rates, solving some of the pressing challenges in bringing innovative medicines to market effectively. Jeeva plans to use the GAP Funds investment to advance customer pilot projects and use cases for further validation.
Source: Press release
April 30, 2019
Industry Leaders Outline Five Important Elements Impacting Rare Disease Drug Development
Leaders from AstraZeneca, American Gene Technologies, REGENXBIO, GeneDX, and Jeeva Informatics Solutions recently converged on the newly redesigned 704 Quince Orchard innovation space in Gaithersburg, Maryland for a panel discussion on drug development and rare disease.
September 12, 2018
Summer Internship Program in Precision Medicine Creates a Win-Win for Students and Local Company
Technologies such as cloud, bigdata, nosql databases, mobile apps, wearable sensors, and healthcare data interoperability are buzz words to many, but they are technologies that are propelling the healthcare-IT field forward into new frontiers. The possibilities these technologies bring can aide in patient engagement, data aggregation, integration and analytics for precision medicine. This is the cutting-edge space that Jeeva Informatics, a local company, operates in. It’s also a very attractive field for students who are eager to get work experience in the emerging technologies of the future.